Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer



Status:Active, not recruiting
Conditions:Cancer, Cancer, Pancreatic Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:8/23/2017
Start Date:October 2010
End Date:December 2018

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Expression Patterns of Stem Cell Marker Doublecortin and CaM Kinase-Like-1 (DCAMKL-1) in Human Pancreatic Adenocarcinoma

The investigators believe DCAMKL-1 is a stem cell tumor marker and is elevated in patients
with pancreatic cancer. The investigators would like to analyze its expression pre and post
treatment, to gauge the correlation between current pancreatic cancer therapies and the
expression of DCAMKL-1


Inclusion Criteria:

- pancreatic cancer

Exclusion Criteria:

- age < 18, history of other types of cancer
We found this trial at
1
site
Stephensen Cancer Center
800 Northeast 10th Street
Oklahoma City, Oklahoma 73104
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials